{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.17","upperLimit":"72.33","value":"41.67"},{"groupId":"OG001","lowerLimit":"30.79","upperLimit":"89.07","value":"63.64"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"Improvement in blood pressure was defined as a participant who experiences at least a 5 mmHg decrease in mean diastolic or systolic BP from baseline who has not taken an additional antihypertensive medication during the treatment period or increased the dosage of a concurrent antihypertensive medication.","dispersionType":"95% Confidence Interval","groups":[{"description":"100 mg/day for 4 weeks in Period 1, then 150 mg/day for 4 weeks in Period 2, then 200 mg/day for 4 weeks in Period 3. Period 3 was followed by a 4-week follow-up period.","id":"OG000","title":"Group 1: Low-dose Group"},{"description":"250 mg/day for 4 weeks in Period 1, then 300 mg/day for 4 weeks in Period 2, then 350 mg/day for 4 weeks in Period 3, then 400 mg/day for 4 weeks in Period 4. Period 4 was followed by a 4-week follow-up period.","id":"OG001","title":"Group 2: High-dose Group"}],"paramType":"NUMBER","populationDescription":"All enrolled participants with hypertension at Baseline who received at least one dose of study drug and had at least one post-baseline assessment.","reportingStatus":"POSTED","timeFrame":"Group 1: Week 12 or last observation; Group 2: Week 16 or last observation","title":"Percentage of Participants With Hypertension Who Experience Improvement in Blood Pressure Following Treatment With CORT125134","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}